Antidiabetic effect of methanolic extract from berberis julianae schneid. via activation of amp-activated protein kinase in type 2 diabetic mice

Evidence-based Complementary and Alternative Medicine

Volumn 2014, Issue , 2014, Pages

  Yang, Jing ^a   Zhao, Ping ^a   Wan, Dingrong ^a   Zhou, Qi ^a   Wang, Chao ^a   Shu, Guangwen ^a   Mei, Zhinan ^a   Yang, Xinzhou ^a  

^a SOUTH CENTRAL UNIVERSITY FOR NATIONALITIES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BERBERIS JULIANAE SCHNEID METHANOL EXTRACT; FATTY ACID; GLUCOSE; GLUCOSE TRANSPORTER 4; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; METHANOL; PLANT EXTRACT; STREPTOZOCIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; BERBERIS; BERBERIS JULIANAE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; FAT MASS; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN TOLERANCE TEST; LIPID BLOOD LEVEL; LIPID DIET; MALE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET; PLANT ROOT; PRIORITY JOURNAL; SKELETAL MUSCLE; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84931284087     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2014/106206     Document Type: Article

References (44)

1. M. Arrese, "Nonalcoholic fatty liver disease: liver disease: an overlooked complication of diabetes mellitus," Nature Reviews Endocrinology, vol. 6, no. 12, pp. 660-661, 2010.
2. H. King, R. E. Aubert, and W. H. Herman, "Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections," Diabetes Care, vol. 21, no. 9, pp. 1414-1431, 1998.
3. W. K. Oh, C. H. Lee, M. S. Lee et al., "Antidiabetic efects of extracts from Psidium guajava," Journal of Ethnopharmacology, vol. 96, no. 3, pp. 411-415, 2005.
4. E. S. Horton, "Can newer therapies delay the progression of type 2 diabetes mellitus?" Endocrine Practice, vol. 14, no. 5, pp. 625-638, 2008.
5. T. Kadowaki, "Insights into insulin resistance and type 2 diabetes from knockout mouse models," Journal of Clinical Investigation, vol. 106, no. 4, pp. 459-465, 2000.
6. A. J. Evans and A. J. Krentz, "Recent developments and emerging therapies for type 2 diabetes mellitus," Drugs in R & D, vol. 2, no. 2, pp. 75-94, 1999.
7. W. L. Li, H. C. Zheng, J. Bukuru, and N. de Kimpe, "Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus," Journal of Ethnopharmacology, vol. 92, no. 1, pp. 1-21, 2004.
8. L. R. Kurukulasuriya and J. R. Sowers, "Terapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors," Cardiovascular Diabetology, vol. 9, article 45, 2010.
9. S. Huang and M. P. Czech, "The GLUT4 glucose transporter," Cell Metabolism, vol. 5, no. 4, pp. 237-252, 2007.
10. A. R. Saltiel and C. R. Kahn, "Insulin signalling and the regulation of glucose and lipid metabolism," Nature, vol. 414, no. 6865, pp. 799-806, 2001.
11. B. B. Kahn and J. S. Flier, "Obesity and insulin resistance," The Journal of Clinical Investigation, vol. 106, no. 4, pp. 473-481, 2000.
12. J. Pan, F. Yin, C. Shen et al., "Studies on the active constituents of the root of Berberis poiretii," Natural Product Research and Development, vol. 2, no. 5, pp. 23-26, 1989.
13. T. Zheng, G. Shu, Z. Yang, S. Mo, Y. Zhao, and Z. Mei, "Antidiabetic efect of total saponins from Entada phaseoloides (L.) Merr. in type 2 diabetic rats," Journal of Ethnopharmacology, vol. 139, no. 3, pp. 814-821, 2012.
14. P. Pushparaj, C. H. Tan, and B. K. H. Tan, "Efects of Averrhoabilimbi leaf extract on blood glucose and lipids in streptozotocin-diabetic rats," Journal of Ethnopharmacology, vol. 72, no. 1-2, pp. 69-76, 2000.
15. Y. S. Lee, W. S. Kim, K. H. Kim et al., "Berberine, a natural plant product, activates AMP-activated protein kinase with benefcial metabolic efects in diabetic and insulin-resistant states," Diabetes, vol. 55, no. 8, pp. 2256-2264, 2006.
16. Z. Lian, Y. Li, J. Gao et al., "A novel AMPK activator, WS070117, improves lipid metabolism discords in hamsters and HepG2 cells," Lipids in Health and Disease, vol. 10, no. 1, article 67, 2011.
17. E. Bartoli, G. P. Fra, and G. P. C. Schianca, "The oral glucose tolerance test (OGTT) revisited," European Journal of Internal Medicine, vol. 22, no. 1, pp. 8-12, 2011.
18. D. E. Moller and K. D. Kaufman, "Metabolic syndrome: a clinical and molecular perspective," Annual Review of Medicine, vol. 56, pp. 45-62, 2005.
19. K. R. Hallows, P. F. Mount, N. M. Pastor-Soler, and D. A. Power, "Role of the energy sensor AMP-activated protein kinase in renal physiology and disease," The American Journal of Physiology-Renal Physiology, vol. 298, no. 5, pp. F1067-F1077, 2010.
20. H. Yki-Jarvinen, "Glucose toxicity," Endocrine Reviews, vol. 13, no. 6, pp. 415-431, 1992.
21. C.-C. Shih, C.-H. Lin, W.-L. Lin, and J.-B. Wu, "Momordica charantia extract on insulin resistance and the skeletal muscle GLUT4 protein in fructose-fed rats," Journal of Ethnopharma-cology, vol. 123, no. 1, pp. 82-90, 2009.
22. E. Carvalho, K. Kotani, O. D. Peroni, and B. B. Kahn, "Adipose-specifc overexpression of GLUT4 reverses insulin resistance and diabetes in mice lacking GLUT4 selectively in muscle," The American Journal of Physiology-Endocrinology and Metabolism, vol. 289, no. 4, pp. E551-E561, 2005.
23. A. Zisman, O. D. Peroni, E. D. Abel et al., "Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance," Nature Medicine, vol. 6, no. 8, pp. 924-928, 2000.
24. K. Kotani, O. D. Peroni, Y. Minokoshi, O. Boss, and B. B. Kahn, "GLUT4 glucose transporter defciency increases hepatic lipid production and peripheral lipid utilization," Journal of Clinical Investigation, vol. 114, no. 11, pp. 1666-1675, 2004.
25. J. T. Brozinick Jr., S. C. McCoid, T. H. Reynolds et al., "GLUT4 overexpression in db/db mice dose-dependently ameliorates diabetes but is not a lifelong cure," Diabetes, vol. 50, no. 3, pp. 593-600, 2001.
26. E. B. Katz, A. E. Stenbit, K. Hatton, R. DePinho, and M. J. Charron, "Cardiac and adipose tissue abnormalities but not diabetes in mice defcient in GLUT4," Nature, vol. 377, no. 6545, pp. 151-155, 1995.
27. A. E. Stenbit, T.-S. Tsao, J. Li et al., "GLUT4 heterozygous knockout mice develop muscle insulin resistance and diabetes," Nature Medicine, vol. 3, no. 10, pp. 1096-1101, 1997.
28. E. D. Abel, O. Peroni, J. K. Kim et al., "Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver," Nature, vol. 409, no. 6821, pp. 729-733, 2001.
29. Y. Minokoshi, C. R. Kahn, and B. B. Kahn, "Tissue-specifc ablation of the glut4 glucose transporter or the insulin receptor challenges assumptions about insulin action and glucose homeostasis," Journal of Biological Chemistry, vol. 278, no. 36, pp. 33609-33612, 2003.
30. J. Shi and K. V. Kandror, "Sortilin is essential and sufcient for the formation of glut4 storage vesicles in 3T3-L1 adipocytes," Developmental Cell, vol. 9, no. 1, pp. 99-108, 2005.
31. J. Shi and K. V. Kandror, "The luminal Vps10p domain of sortilin plays the predominant role in targeting to insulin-responsive Glut4-containing vesicles," The Journal of Biological Chemistry, vol. 282, no. 12, pp. 9008-9016, 2007.
32. A. Kumar, J. C. Lawrence, and D. Y. Jung, "Fat cellspecifc ablation of rictor in mice impairs insulin-regulated fat cell and whole-body glucose and lipid metabolism," Diabetes, vol. 59, no. 6, pp. 1397-1406, 2010.
33. B. R. Rubin and J. S. Bogan, "Intracellular retention and insulin-stimulated mobilization of GLUT4 glucose transporters," Vitamins & Hormones, vol. 80, pp. 155-192, 2009.
34. S. R. Keller, A. C. Davis, and K. B. Clairmont, "Mice def-cient in the insulin-regulated membrane aminopeptidase show substantial decreases in glucose transporter GLUT4 levels but maintain normal glucose homeostasis," The Journal of Biological Chemistry, vol. 277, no. 20, pp. 17677-17686, 2002.
35. A. G. Bertoni, W. G. Hundley, M. W. Massing, D. E. Bonds, G. L. Burke, and D. C. Gof Jr., "Heart failure prevalence, incidence, and mortality in the elderly with diabetes," Diabetes Care, vol. 27, no. 3, pp. 699-703, 2004.
36. P. Kovacs and M. Stumvoll, "Fatty acids and insulin resistance in muscle and liver," Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 19, no. 4, pp. 625-635, 2005.
37. S. Subramanian and A. Chait, "Hypertriglyceridemia secondary to obesity and diabetes," Biochimica et Biophysica Acta-Mole-cular and Cell Biology of Lipids, vol. 1821, no. 5, pp. 819-825, 2012.
38. P. Bansal, P. Paul, J. Mudgal et al., "Antidiabetic, antihyperlipi-demic and antioxidant efects of the favonoid rich fraction of Pilea microphylla (L.) in high fat diet/streptozotocin-induced diabetes in mice," Experimental and Toxicologic Pathology, vol. 64, no. 6, pp. 651-658, 2012.
39. D. Carling, "The AMP-activated protein kinase cascade-a unifying system for energy control," Trends in Biochemical Sciences, vol. 29, no. 1, pp. 18-24, 2004.
40. J. K. Eun, S.-N. Jung, H. S. Kun et al., "Antidiabetes and antiobesity efect of cryptotanshinone via activation of AMP-activated protein kinase," Molecular Pharmacology, vol. 72, no. 1, pp. 62-72, 2007.
41. B. B. Zhang, G. Zhou, and C. Li, "AMPK: an emerging drug target for diabetes and the metabolic syndrome," Cell Metabolism, vol. 9, no. 5, pp. 407-416, 2009.
42. J. M. Ye, N. B. Ruderman, and E. W. Kraegen, "AMP-activated protein kinase and malonyl-CoA: targets for treating insulin resistance?" Drug Discovery Today: Terapeutic Strategies, vol. 2, no. 2, pp. 157-163, 2005.
43. M. A. Iglesias, J. M. Ye, G. Frangioudakis et al., "AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats," Diabetes, vol. 52, no. 10, pp. 2886-2894, 2002.
44. N. Musi, "AMP-activated protein kinase and type 2 diabetes," Current Medicinal Chemistry, vol. 13, no. 5, pp. 583-589, 2006.